Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

被引：0
|
作者：
Su, Yi-Jiun
Kuo, Ming-Chung
Teng, Chieh-Lin
Chen, Tsai-Yun
Ma, Ming-Chun
Hsiao, Pei-Ching
Wang, Ming-Chung
Lin, Tung-Huei
Hwang, Wen-Li
Chen, Chih-Cheng
Yang, Youngsen
Pei, Sung-Nan
Huang, Yen-Min
Li, Sin-Syue
Lee, Ming-Yang
Cheng, Hung-I
Shih, Lee-Yung
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1603
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Molecular Responses at 3 and 6 Months Predict Outcomes in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Front-line lmatinib: Taiwan CML Study Group
    Kuo, Ming-Chung
    Chen, Tsai-Yun
    Wang, Ming-Chung
    Lin, Tseng-Hsi
    Bai, Li-Yaun
    Lan, Yii-Jenq
    Chen, Chih-Cheng
    Hsiao, Pei-Ching
    Hwang, Wen-Li
    Yeh, Su-Peng
    Kuo, Ching-Yuan
    Shih, Lee-Yung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S138 - S138
  • [22] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
    Jabbour, Elias
    Kantarjian, Hagop M.
    O'Brien, Susan
    Shan, Jianqin
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Rios, Mary Beth
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
  • [23] DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML)
    Jurcek, T.
    Razga, F.
    Jeziskova, I.
    Zackova, D.
    Mayer, J.
    Dvorakova, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 676 - 676
  • [24] CLINICAL SIGNIFICANCE OF COMBINING BCR-ABL1 TRANSCRIPT LEVELS AT 3 AND 6 MONTHS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FRONTLINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S. E.
    Choi, S. Y.
    Kim, S. H.
    Oh, Y. J.
    Chae, M. J.
    Song, H. Y.
    Yoo, H. L.
    Lee, M. Y.
    Jang, E. J.
    Jeong, K. H.
    Lee, J. S.
    Kim, D. W.
    HAEMATOLOGICA, 2014, 99 : 599 - 599
  • [25] MOLECULAR RESPONSES OF B2A2 BCR-ABL1 TRANSCRIPT ARE INFERIOR TO B3A2 TYPE IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT CHRONIC PHASE TREATED WITH FRONTLINE IMATINIB -TAIWAN CML STUDY
    Wang, M. C.
    Kuo, M. C.
    Chen, T. Y.
    Yang, Y.
    Yeh, S. P.
    Chen, C. C.
    Su, Y. C.
    Hsiao, P. C.
    Lee, M. Y.
    Hwang, W. L.
    Kuo, C. Y.
    Lin, T. H.
    Shih, L. Y.
    HAEMATOLOGICA, 2016, 101 : 236 - 236
  • [26] E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
    Claudiani, Simone
    Apperley, Jane F.
    Gale, Robert Peter
    Clark, Richard
    Szydlo, Richard
    Deplano, Simona
    Palanicawandar, Renuka
    Khorashad, Jamshid
    Foroni, Letizia
    Milojkovic, Dragana
    HAEMATOLOGICA, 2017, 102 (08) : E297 - E299
  • [27] Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia
    Langabeer, Stephen E.
    McCarron, Sarah L.
    Carroll, Peig
    Kelly, Johanna
    O'Dwyer, Michael
    Conneally, Eibhlin
    LEUKEMIA RESEARCH, 2011, 35 (09) : E169 - E170
  • [28] Molecular responses to tyrosine kinase inhibitors in rare, variant e1a2, e6a2 and e19a2 BCR-ABL chronic myeloid leukaemia
    Langabeer, S. E.
    Crampe, M.
    McCarron, S. L.
    Haslam, K.
    Connaghan, G.
    Perera, K.
    Cahill, M. R.
    Conneally, E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 74 - 74
  • [29] The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors
    D'Adda, Mariella
    Farina, Mirko
    Schieppati, Francesca
    Borlenghi, Erika
    Bottelli, Chiara
    Cerqui, Elisa
    Ferrari, Samantha
    Gramegna, Doriana
    Pagani, Chiara
    Passi, Angela
    Maifredi, Adriana
    Tucci, Alessandra
    Capucci, Maria A.
    Ruggeri, Giuseppina
    Rossi, Giuseppe
    CANCER, 2019, 125 (10) : 1674 - 1682
  • [30] OUTCOMES OF THIRD-LINE BCR-ABL1 TYROSINE KINASE INHIBITORS IN THE TREATMENT FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE RECEIVED TWO PRIOR TKIS
    Lee, S. E.
    Choi, S. Y.
    Kim, S. H.
    Oh, Y. J.
    Chae, M. J.
    Song, H. Y.
    Yoo, H. L.
    Lee, M. Y.
    Jang, E. J.
    Jeong, K. H.
    Lee, J. S.
    Kim, D. W.
    HAEMATOLOGICA, 2014, 99 : 335 - 335
12345